Floatz logo

Thalidomide

Tuberculosis

National Center for Research Resources (NCRR)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Tuberculosis cohort.

Asset / SponsorPhaseRating
SULFAMETHOXAZOLE
Texas Tech University Health Sciences Center
Phase 4BB
Trimethoprim
Texas Tech University Health Sciences Center
Phase 4BB
ETHAMBUTOL
Texas Tech University Health Sciences Center
Phase 4BB
Dapsone
Texas Tech University Health Sciences Center
Phase 4BB
Selenium
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3BB

View all 13 →

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →